Nexplanon (Etonogestrel)

Etonogestrel, the active ingredient in Nexplanon, binds to progesterone receptors, suppressing the luteinizing hormone surge and preventing ovulation. It also thickens cervical mucus and alters the endometrium, creating multiple barriers to fertilisation and implantation.

The implant contains a fixed 68 mg of etonogestrel that releases a low, steady dose over three years. The exact dosing schedule and insertion timing are determined by the prescribing clinician based on individual patient needs.

Nexplanon must not be used by women who are already pregnant. If pregnancy occurs, the implant should be removed promptly. Breastfeeding is not an absolute contraindication, but healthcare providers should discuss potential benefits and risks with the patient.

To place an order, submit an enquiry on the Nexplanon product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with daily oral contraceptives, Nexplanon offers continuous protection without the need for daily adherence. Unlike intra‑uterine devices, it is placed subcutaneously in the upper arm and can be removed easily. Its efficacy is comparable to other long‑acting reversible methods, with a failure rate of less than 1 % when correctly inserted.

Nexplanon should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperatures. During transport, keep the implant in a temperature‑controlled environment to maintain product integrity.

A trained healthcare professional inserts Nexplanon subcutaneously into the inner side of the upper arm using a pre‑filled applicator. The procedure is performed in a clinical setting under aseptic conditions, and the implant remains in place for up to three years unless removal is required earlier.

Serious risks include deep‑vein thrombosis or pulmonary embolism, severe allergic reactions such as anaphylaxis, and implant migration that can make removal difficult. Patients should seek immediate medical attention if they experience unexplained leg pain, swelling, shortness of breath, or signs of a severe allergic response.

Nexplanon is contraindicated in women who are pregnant, have active liver disease, a history of thromboembolic disorders, hormone‑sensitive cancers, or unexplained vaginal bleeding. It should also be avoided in individuals with known hypersensitivity to etonogestrel or any component of the implant.